Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patients Assess Preference Assessment Tool for MS

Int J MS Care; ePub 2018 Jan 25; Col, Solomon, et al

A newly-developed preference assessment tool successfully captured patients' goals, values, and preferences for multiple sclerosis (MS) treatment and could potentially be used to help patients communicate their preferences to their clinician, according to a recent investigation. Patients with MS between the ages of 21 and 75 who had access to the Internet (n=135) were recruited. They completed the preference tool online, which included separate modules assessing 3 core preference areas: treatment goals, preferences for attributes of disease-modifying therapies (DMTs), and factors influencing a change in treatment. Immediately after viewing a summary of their treatment goals and preferences, participants were asked to evaluate the tool. Rankings of preference domains were compared to rankings obtained in another study. Investigators found:

  • The highest ranked goals were brain health (memory, thinking, and brain), followed by disability concerns (walking, strength, vision).
  • Rankings were highly similar to those in the referent study.
  • Nearly all participants reported that the tool helped them understand their goals and priorities regarding MS and that the summary appropriately reflected what is important to them.
  • Most (87%) expressed a desire to discuss their treatment goals and priorities with their clinician.


Col NF, Solomon AJ, Springmann V, et al. Evaluation of a novel preference assessment tool for patients with multiple sclerosis. [Published online ahead of print January 25, 2018]. Int J MS Care. doi:10.7224/1537-2073.2017-021.

This Week's Must Reads

Readmission Rates After Thrombectomy for Stroke , J Stroke Cerebrovasc Dis; ePub 2018 Jul 3; Ramchand, et al

Admissions for Psychotic Episodes, Epilepsy Linked , Epilepsia; ePub 2018 Jul 4; Rossi, Kim, et al

Gender and Cognition in Overweight Adults with T2D, Alzheimers Dement; ePub 2018 Jul 4; Espeland, et al

Subjective Improvements in Sleep Apnea Examined, Sleep Med; ePub 2018 Jul 4; Bhat, Gupta, et al

FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3

Must Reads in Multiple Sclerosis

Brain Volume Loss as Therapeutic Response Marker , JAMA Neurology; ePub 2018 Jul 2; Andorra, et al

Assessing Environmental Factors and Risk of MS, Mult Scler Relat Disord; ePub 2018 Jun 23; Mowry, et al

Fear of Falling Impacts Leisure-Time Activity in MS, Gait Posture; ePub 2018 Jun 30; Kalron, Aloni, et al

Identifying Anxiety Symptoms in Multiple Sclerosis, Arch Phys Med Rehab; ePub 2018 Jun 30; Hughes, et al

Spinal Cord Volume Loss: Marker of MS Progression, Neurology; ePub 2018 Jun 27; Tsagkas, Magon, et al